Five things for pharma marketers to know: Wednesday, April 4, 2018

Share this content:

The final tally for signups for healthcare coverage through the Affordable Care Act for 2018 was 11.8 million, 400,000 less than last year. However, the open enrollment period was shorter than in past years and the Trump administration cut outreach funding. (New York Times)


Federal officials are warning about the outbreak of “nightmare bacteria,” which is resistant to most antibiotics. Officials from the Centers for Disease Control and Prevention said aggressive countermeasures could slow the spread of the bacteria. (NBC News)


Ohio's Insurance Department has demanded insurers and pharmacy benefit managers tell consumers if more affordable prescription drug options are available. The provisions are set to go into effect immediately. (Reuters)


Eli Lilly and Sigilon are set to announce a $473 million pact to advance stem-cell research on Type 1 diabetes. Eli Lilly is also planning an unspecified investment in Sigilon, a startup based in Cambridge, Massachusetts, that launched last year. (Endpoints).


The FDA is using new powers to order a mandatory recall of kratom products. The government agency is targeting Triangle Pharmanaturals with a recall of several kratom products that were found to contain salmonella. (Fortune)


Share this content:
Scroll down to see the next article